CLSN Share Price | Imunon, Inc. Stock Analysis & Recommendation

Q: What does Imunon, Inc. do?

Overview:Imunon, Inc. is an oncology drug development company operating in the Pharmaceuticals & Biotechnology industry, with a market cap of USD 22.96 million.Financial Snapshot:Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) Market cap: USD 22.96 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -2.48 Return on Equity: -1,779.32% Price to Book: 22.96 Contact Details:Address: 997 Lenox Dr Ste 100, LAWRENCE TOWNSHIP NJ: 08648-2317 Tel: 1 609 8969100 Fax: 1 609 8962200 Website: http://celsion.com/

Q: Is Imunon, Inc. technically bullish or bearish?

As of 10 September 2025, the technical trend for Imunon, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the weekly MACD and Bollinger Bands both signaling bearish conditions. The daily moving averages also confirm a bearish outlook. The Dow Theory reflects a mildly bearish sentiment on the weekly and monthly time frames, while the KST is bearish across both periods. The OBV shows a mildly bearish trend weekly but is bullish monthly, indicating some divergence. There is no multi-period return data available to compare the stock's performance against the S&P 500.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

7.82 k

Shareholding (Dec 2025)

FII

0.25%

Held by 7 FIIs

DII

97.91%

Held by 2 DIIs

Promoter

0.00%

How big is Imunon, Inc.?

22-Jun-2025

As of Jun 18, Imunon, Inc. has a market capitalization of 22.96 million, with net sales of 0.00 million and a net profit of -17.80 million. Shareholder's funds are 4.24 million and total assets are 9.72 million.

View full answer

What does Imunon, Inc. do?

22-Jun-2025

Imunon, Inc. is an oncology drug development company in the Pharmaceuticals & Biotechnology sector, with a market cap of USD 22.96 million and a recent net profit of -4 million. The company has no dividend yield and significant negative return on equity.

View full answer

Who are in the management team of Imunon, Inc.?

22-Jun-2025

As of March 2022, the management team of Imunon, Inc. includes Michael Tardugno as Executive Chairman, President, and CEO, along with independent directors Dr. Donald Braun, Dr. Pok Yu Chow, Frederick Fritz, Robert Hooper, and Mr. Andreas Voss.

View full answer

Is Imunon, Inc. technically bullish or bearish?

20-Sep-2025

As of September 10, 2025, Imunon, Inc. has shifted to a bearish trend with weak strength indicators, supported by bearish signals from the MACD, Bollinger Bands, and daily moving averages, while showing some divergence in the OBV.

View full answer

Compare Imunon, Inc. with Similar Stocks

Organovo Holdings, Inc.Landos Biopharma, Inc.Dominari Holdings, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 10 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.69%

Debt Equity

-1.19

Return on Equity

-351.06%

Price to Book

2.52

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-4 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-16.82%

6 Months

-32.0%

1 Year

-75.03%

2 Years

-86.1%

3 Years

95.68%

4 Years

-93.36%

5 Years

-98.7%

Imunon, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-12.94%

EBIT Growth (5y)

3.91%

EBIT to Interest (avg)

-15.72

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-2.48

Sales to Capital Employed (avg)

0.01

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

9.63%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

2.52

EV to EBIT

-0.37

EV to EBITDA

-0.39

EV to Capital Employed

-5.41

EV to Sales

PEG Ratio

Dividend Yield

0.69%

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-351.06%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bearish

Mildly Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 2 Schemes (1.84%)

Foreign Institutions

Held by 7 Foreign Institutions (0.25%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -2.44% vs 16.33% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.10",
          "val2": "-4.00",
          "chgp": "-2.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.20",
          "val2": "-4.10",
          "chgp": "-2.44%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 22.04% vs 4.62% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-14.00",
          "val2": "-18.40",
          "chgp": "23.91%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-14.50",
          "val2": "-18.60",
          "chgp": "22.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-4.10

-4.00

-2.50%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-4.20

-4.10

-2.44%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -2.44% vs 16.33% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-14.00

-18.40

23.91%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-14.50

-18.60

22.04%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 22.04% vs 4.62% in Dec 2024

All Annual Results

Company CV

About Imunon, Inc.

Imunon, Inc.

Pharmaceuticals & Biotechnology

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Company Coordinates

Company Details

997 Lenox Dr Ste 100 , LAWRENCE TOWNSHIP NJ : 08648-2317

Tel: 1 609 89691001 609 8969100

http://celsion.com/

Registrar Details